Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T MacLaughlin

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Molecular and Cellular Endocrinology|December 6, 2003
MIS/AMH in the assessment of cryptorchidism and intersex conditionsMary M Lee, Madhusmita Misra, Patricia K Donahoe, et al.
Molecular and Cellular Endocrinology|December 6, 2003
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applicationsPatricia K Donahoe, Trent Clarke, Jose Teixeira, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2003
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107Thanh U Barbie, David A Barbie, David T MacLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2004
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceElizabeth J Renaud, David T MacLaughlin, Esther Oliva, et al.
Fertility and Sterility|March 2, 2002
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cyclesDavid B Seifer, David T MacLaughlin, Benjamin P Christian, et al.
Fertility and Sterility|January 18, 2005
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatmentRichard Fleming, Lyndal Harborne, David T MacLaughlin, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 1, 2002
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivityHans K Lorenzo, Jose Teixeira, Nima Pahlavan, et al.
Gynecologic Oncology|November 9, 2010
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell linesHenry L Chang, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, et al.
Developmental Biology|November 18, 2008
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian ductAkihiro Fujino, Nelson A Arango, Yong Zhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivoAntonia E Stephen, Lisa A Pearsall, Benjamin P Christian, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Molecular and Cellular Endocrinology|December 6, 2003
MIS/AMH in the assessment of cryptorchidism and intersex conditionsMary M Lee, Madhusmita Misra, Patricia K Donahoe, et al.
Molecular and Cellular Endocrinology|December 6, 2003
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applicationsPatricia K Donahoe, Trent Clarke, Jose Teixeira, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2003
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107Thanh U Barbie, David A Barbie, David T MacLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2004
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceElizabeth J Renaud, David T MacLaughlin, Esther Oliva, et al.
Fertility and Sterility|March 2, 2002
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cyclesDavid B Seifer, David T MacLaughlin, Benjamin P Christian, et al.
Fertility and Sterility|January 18, 2005
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatmentRichard Fleming, Lyndal Harborne, David T MacLaughlin, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 1, 2002
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivityHans K Lorenzo, Jose Teixeira, Nima Pahlavan, et al.
Gynecologic Oncology|November 9, 2010
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell linesHenry L Chang, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, et al.
Developmental Biology|November 18, 2008
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian ductAkihiro Fujino, Nelson A Arango, Yong Zhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivoAntonia E Stephen, Lisa A Pearsall, Benjamin P Christian, et al.
Pageof 5